TITLE

SIMCERE PHARMACEUTICAL AQUIRES 70% STAKE IN WUHU ZONG REN

PUB. DATE
June 2008
SOURCE
Worldwide Biotech;Jun2008, Vol. 20 Issue 6, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article reports on a definitive agreement signed by Simcere Pharmaceutical Group to acquire an equity interest in Wuhu Zhong Ren Pharmaceutical Co. This transaction is consistent with the strategy of Simcere to focus on first-to-market and innovative new drugs and expand its anti-cancer product portfolio. WuHu Zhong is a Chinese drug manufacturer specializing in the production of sustained release anti-tumor implants.
ACCESSION #
32474192

 

Related Articles

  • Tigermed Cooperates with Simcere in Drugs R&D.  // China Chemical Reporter;12/26/2009, Vol. 20 Issue 36, p13 

    The article announces the partnership agreement signed by the leading Contract Research Organization (CRO) Tigermed Consulting Co. Ltd. and Jiangsu Simcere Pharmaceutical Group in China. It states that the agreement will see the two companies to collaborate in many aspects pertaining to medicine...

  • This week in BioWorld Asia.  // BioWorld Today;1/2/2013, Vol. 25 Issue 1, p1 

    A list of topics featured in the journal "BioWorld Asia" in January 2014 is presented including the plans of the Chinese government to relaunch its biopharmaceutical market, the privatization of Simcere Pharmaceutical Group, and the partnership of China's drug importer with BioCubaFarma.

  • Cardiology Sector to Boom.  // Chain Drug Review;1/16/2012, Vol. 34 Issue 2, p61 

    The article offers various information related to cardiology in the U.S. including the U.S. Food and Drug Administration's (FDA's) approval to Edarbyclor, the expansion of the partnership between Simcere Pharmaceutical Group and Bristol-Myers Squibb Co., and prediction for anticoagualants' boost.

  • Simcere Pharmaceutical Receives $500M Proposal to Go Private. COLLINS, ALLISON // Mergers & Acquisitions Report;3/18/2013, Vol. 26 Issue 11, p4 

    The article reports on a 500 million U.S. dollars buyout offer received by Simcere Pharmaceutical Group from the chairman of its board of directors, Jinsheng Ren.

  • Fresh from the pipeline: Gefitinib. Muhsin, Mohamed; Graham, Joanne; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Jul2003, Vol. 2 Issue 7, p515 

    Gefitinib (Iressa; AstraZeneca) is the first in a new class of targeted anticancer drugs that inhibit the tyrosine kinase activity of the epidermal growth factor receptor. Following Japanese approval in 2002, gefitinib was approved by the US FDA in May 2003 for the treatment of advanced...

  • In this issue.  // Nature Reviews Drug Discovery;Nov2010, Vol. 9 Issue 11, p821 

    The article discusses various reports published within the issue, including one by Brinkmann and colleagues on the case history of fingolimod, one by Cohen on cyclical development strategy, and one by Doroshow and colleagues on their evaluation of anticancer agents at the U.S. National Cancer...

  • Anticancer chemotherapy. Davey, Peter; Tudhope, G.R. // British Medical Journal (Clinical Research Edition);7/9/1983, Vol. 287 Issue 6385, p107 

    Features several of the latest cytotoxic drugs and its applications in Great Britain. Current drugs and their analogues; Developments with antimetabolites; Enumerations on latest cytotoxic drugs.

  • Current Targets for Anticancer Drug Discovery. N-H. Nam; K. Parang // Current Drug Targets;Feb2003, Vol. 4 Issue 2, p159 

    The call for the discovery of less toxic, more selective, and more effective agents to treat cancer has become more urgent. Inhibition of angiogenesis continues to be one of the main streams in the current cancer drug discovery activity. Insights into tumor angiogenesis biology have led to the...

  • Human tyrosyl-DNA phosphodiesterase 1: new activities and development of enzyme inhibitors as anticancer drugs. Lavrik, O. // Biopolymers & Cell;2015 Suppl. 5, p13 

    Tyrosyl-DNA phosphodiesterase 1 (TDP1) is responsible to process topoisomerase 1 (TOP1) - DNA adducts as well as to hydrolyze a variety of other DNA 3'-substituents. We have shown recently that TDP1 can initiate repair of apurinic/apyrimidinic (AP) sites located in the internal positions of DNA...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics